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ABSTRACT
The possibility of using gene therapy for the treatment of prostate cancer is limited by the lack of
intravenously administered delivery systems able to safely and selectively deliver therapeutic genes to
tumors. Given that lactoferrin (Lf) receptors are overexpressed on prostate cancer cells, we hypothe-
sized that the conjugation of Lf to generation 3-diaminobutyric polypropylenimine dendrimer would
improve its transfection and therapeutic efficacy in prostate cancer cells. In this study, we demon-
strated that the intravenous administration of Lf-bearing DAB dendriplexes encoding TNFa resulted in
the complete suppression of 70% of PC-3 and 50% of DU145 tumors over one month. Treatment with
DAB-Lf dendriplex encoding TRAIL led to tumor suppression of 40% of PC-3 tumors and 20% of
DU145 tumors. The treatment was well tolerated by the animals. Lf-bearing generation 3-polypropyle-
nimine dendrimer is therefore a highly promising delivery system for non-viral gene therapy of pros-
tate cancer.
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Introduction
Prostate cancer is the fourth most widespread cancer in the
world, the second most common cancer in men, and the first
in Europe and North America (Ferlay et al., 2015). It is respon-
sible of the death of 300 000 patients per year worldwide
and its incidence kept on increasing during the last two dec-
ades (Saman et al., 2014). Although cryoablation, chemother-
apy, radiotherapy, and radical prostatectomy can be
efficacious against localized tumors, there is still no effective
treatment for patients with recurrent or metastatic disease
(Lu, 2009). New therapeutic approaches are therefore
urgently needed for these patients.
Among novel experimental strategies, gene therapy would
be highly promising for the treatment of prostate cancer, but
its use is currently limited by the lack of delivery systems
able to selectively deliver the therapeutic genes to the
tumors following intravenous administration, without creat-
ing secondary effects to healthy tissues.
In order to remediate this issue, we propose to conjugate
the iron-carrier lactoferrin (Lf), whose receptors are overex-
pressed on prostate cancer cell lines (Barresi & Tuccari, 1984;
Tuccari & Barresi, 2011), to the surface of generation 3-diami-
nobutyric polypropylenimine (DAB) dendrimer carrying
plasmids encoding for TNFa, TRAIL, or IL-12, and evaluate if
these Lf-bearing dendriplexes could lead to an enhanced
therapeutic efficacy on prostate cancer following intravenous
administration.
Lactoferrin (Lf) is an iron-binding member of the transfer-
rin family, which has been shown to have intrinsic anti-
tumoral activity, making it particularly attractive as part of a
gene medicine. Lf binds to specific receptors (Lf R1, Lf R2) or
to transferrin receptors overexpressed on most cancers lines
(Barresi & Tuccari, 1984; Tuccari & Barresi, 2011). It has been
shown to exert its anticancer effect through modulation of
the mitogen-activated protein kinase signaling pathway and
induction of cell cycle arrest, and can also induce apoptosis
of cancer cells by activating the Fas signaling pathway in
cancerous cells (Zhou et al., 2008; Gibbons et al., 2011).
TNFa, an inflammatory cytokine, is well known for its abil-
ity to induce apoptosis in a wide variety of cancer cells,
including prostate cancer cells. Fas-sensitive PC-3 prostate
cancer cells were reported to be more sensitive to TNFa-
mediated apoptosis and growth inhibition than Fas-resistant
DU145 and LNCaP cells (Rokhlin et al., 1997). In addition,
TNF-a is able to act on the tumor-associated vasculature by
inducing hyperpermeability and destruction of the vascular
lining.
TRAIL, a member of the TNF family of cytokines, presents
the particularly promising advantage to induce apoptosis
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preferentially in cancer cells whilst sparing normal cells (van
Ophoven et al., 1999). Its binding to death receptors DR4
and DR5 resulted in the recruitment of Fas-associated death
domain, and cancer cell death via caspase-dependent apop-
totic pathways (van Ophoven et al., 1999).
Another cytokine, IL-12, exerts its anti-cancer effect using
various mechanisms such as activation of potent antitumor
immunity, induction of interferon-gamma, interferon-indu-
cible protein-10 (IP-10), and regulation of Th1 cell differenti-
ation (Gately et al., 1998; Tannenbaum et al., 1998). In animal
melanoma models, the administration of IL-12 plasmid
resulted in inhibition of tumor growth and regression of
established tumors (Lucas et al., 2002), but is also limited by
its potential side effects (Leonard et al., 1997), thus highlight-
ing the need of a tumor-targeted delivery system for deliver-
ing this plasmid to its site of action.
The objectives of this study were therefore (1) to synthe-
size and characterize Lf-bearing DAB dendrimer, (2) to assess
the transfection and anti-proliferative efficacy of the DAB-Lf
dendriplexes encoding TNFa, TRAIL, or IL-12, on prostate can-
cer cells in vitro, and (3) to evaluate their therapeutic efficacy
in vivo, following intravenous administration to mice bearing
prostate tumors.
Methods
Cell lines and reagents
Generation 3-diaminobutyric polypropylenimine dendrimer
(DAB), Lf, and the other chemicals were purchased from
Sigma Aldrich (Poole, UK). The cross-linker N-c-maleimidobu-
tyryl-oxysuccinimide ester (GMBS) was from PolyPeptide
(Strasbourg, France). The expression plasmids encoding b-gal-
actosidase (pCMVsport b-galactosidase) and TNFa (pORF9-
mTNFa) were obtained respectively from Invitrogen (Paisley,
UK) and InvivoGen (San Diego, CA), the expression plasmids
encoding TRAIL (pORF9-mTRAIL) and IL-12 (pORF-mIL12)
came from Source BioScience (Nottingham, UK). All these
plasmids were purified using an Endotoxin-free Giga Plasmid
Kit (Qiagen, Hilden, Germany). Quant-iTTM PicoGreen
VR
dsDNA
reagent, AlexaFluor
VR
647 phalloidin probes and tissue culture
media were purchased from Life Technologies (Paisley, UK).
Vectashield
VR
mounting medium containing 40,6-diamino-2-
phenylindole (DAPI) was obtained from Vector Laboratories
(Peterborough, UK). Label IT
VR
Fluorescein Nucleic Acid
Labeling Kit was from Cambridge Biosciences (Cambridge,
UK). Passive lysis buffer was obtained from Promega
(Southampton, UK). AgarGel H/M agarose was from
Continental Laboratory Products (Northampton, UK).
HyperLadder I was from Bioline (London, UK). Firefly D-luci-
ferin and Bioware
VR
androgen-irresponsive PC-3M-luc-C6
human prostate adenocarcinoma that expresses the firefly
luciferase were from Caliper Life Sciences (Hopkinton, MA),
while androgen-irresponsive DU145 human prostate carcin-
oma was purchased from the European Collection of Cell
Cultures (Salisbury, UK).
Synthesis and characterization of Lf-bearing DAB (in
supplementary material)
Generation 3-diaminobutyric polypropylenimine dendrimer
(DAB) was conjugated to Lf with GMBS as a cross-linking
agent, using a method adapted from Hermanson (2013)
(Supplementary Figure 1). The grafting of Lf to DAB was
assessed by 1H NMR spectroscopy (Jeol Oxford NMR AS 600
spectrometer, Peobody, MA) and MALDI-TOF mass spectros-
copy (Axima CFR, Kratos, Shimadzu, Kyoto, Japan).
In vitro biological characterization
Cell culture
PC-3 and DU145 cells were grown as monolayers in
Minimum Essential Medium (MEM) supplemented with 10%
(v/v) fetal bovine serum, 1% (v/v) L-glutamine, and 0.5% (v/v)
penicillin–streptomycin. The cell culture flasks were kept at
37 C in a 5% carbon dioxide, humid atmosphere.
In vitro transfection
The transfection efficacy of the DNA complexed by DAB-Lf
was assessed using a plasmid DNA encoding b-galactosidase.
PC-3 and DU145 cells were seeded at a concentration of
2000 cells/well in 96-well plates and incubated for 72 h at
37 C in a 5% CO2 atmosphere. They were then treated with
DAB-Lf dendriplex in quintuplicate at various dendrimer: DNA
weight ratios (20:1, 10:1, 5:1, 2:1, 1:1, and 0.5:1). Naked DNA
was used as a negative control and DAB-DNA (dendrimer:
DNA weight ratio 5:1) served as a positive control. DNA con-
centration (10 mg/mL) was kept constant throughout the
experiment. After treatment, the cells were incubated for
72 h before analysis. They were then lysed with 1 passive
lysis buffer (PLB) (50mL/well) for 20min and then tested for
b-galactosidase expression (Zinselmeyer et al., 2002). Briefly,
50 mL of the assay buffer (2mM magnesium chloride, 100mM
mercaptoethanol, 1.33mg/mL O-nitrophenyl- b-D-galactosi-
dase, 200mM sodium phosphate buffer, pH 7.3) was added
in each well containing the lysates, before being incubated
for 2 h at 37 C. The absorbance of the samples was subse-
quently read at 405 nm using a Multiskan Ascent
VR
plate
reader (MTX Lab Systems, Brandenton, FL).
Cellular uptake
Qualitative analysis. The cellular uptake of DAB-Lf dendri-
plex was qualitatively assessed using confocal microscopy.
Labeling of plasmid DNA with the fluorescent probe fluores-
cein was performed using a Label IT
VR
Fluorescein Nucleic
Acid Labeling kit, as described by the manufacturer. PC-3
and DU145 cells were seeded on coverslips in 6-well plates
at a concentration of 105 cells per well and grown for 24 h at
37 C. The cells were then treated with fluorescein-labeled
DNA (2.5 mg/well) complexed to DAB-Lf and DAB at a dendri-
mer: DNA weight ratio of 5:1 for 24 h at 37 C. Control wells
were also prepared with naked DNA or remained untreated.
The cells were then washed three times with 3mL phos-
phate-buffered saline (PBS) before being fixed with 3mL
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formaldehyde solution (3.7%) for 10min at 20 C. They were
then washed again with 3mL PBS, incubated at 20 C with
3mL Triton-X100 solution (0.1%) for 5min, before a further
incubation with 3mL of bovine serum albumin solution (1%
w/v in PBS) for 30min at 37 C. One unit of Alexa Fluor
VR
647
(in 200 mL PBS) was then added to the wells, incubated for
20min at 20 C, before a final wash with 3mL PBS. Upon
staining of the nuclei with Vectashield
VR
mounting medium
containing DAPI, the cells were examined using a Leica TCS
SP5 confocal microscope (Wetzlar, Germany). DAPI (which
stained the cell nuclei) was excited with the 405 nm laser line
(emission bandwidth: 415–491 nm), fluorescein (which
labeled the DNA) was excited with the 514 nm laser line
(emission bandwidth: 550–620 nm), whereas Alexa Fluor
VR
647
(which stained the cell wall) was excited with the 633 nm
laser line (emission bandwidth: 650–690 nm).
Quantitative analysis. Quantification of cellular uptake of
DAB-Lf dendriplex was carried out by flow cytometry. PC-3
and DU145 cells were seeded at a density of 1.6 105 cells
per well in six-well plates and grown at 37 C for 72 h. The
cells were then treated with fluorescein-labeled DNA (5 mg
DNA/well) complexed with DAB-Lf at a dendrimer: DNA
weight ratio of 5:1. Other wells were treated with DAB den-
driplex and DNA solution as positive and negative controls,
respectively.
After 24 h incubation with the treatments, single cell sus-
pensions were prepared (using 250 mL trypsin per well, fol-
lowed by 500 mL medium per well once the cells have
detached), before being analyzed using a FACSCanto
VR
flow
cytometer (BD, Franklin Lakes, NJ). Ten thousand cells (gated
events) were counted for each sample. Their mean fluores-
cence intensity was analyzed with FACSDiva
VR
software (BD,
Franklin Lakes, NJ).
Mechanisms of cellular uptake of DNA complexed to DAB-
Lf. The mechanisms involved in the cellular uptake of DNA
complexed to DAB-Lf were investigated using various uptake
inhibitors. PC-3 and DU145 cells were seeded in six-well
plates (1 105 cells per well) and incubated at 37 C for 24 h
for qualitative analysis or 72 h for quantitative analysis.
After removal of the medium, they were pretreated with
free Lf (80 lM), phenylarsine oxide (10mmol/L), filipin (5 mg/
mL), colchicine (10mmol/L), and poly-L-lysine (40 mg/mL) for
15min at 37 C. The cells were then treated with fluorescein-
labeled DNA (respectively, 2.5 and 5 lg/well for qualitative
and quantitative analysis) complexed to DAB-Lf (dendrimer:
DNA weight ratio of 5:1) for 1 h at 37 C, before being
washed and processed for confocal microscopy and flow
cytometry analysis as described above.
In vitro antiproliferative activity
The antiproliferative activity of Lf-bearing DAB complexed
with plasmid DNA encoding TNFa, TRAIL, or IL-12 was
assessed using a standard MTT assay. PC-3 and DU145 cells
were seeded in quintuplicate at a density of 2000 cells/well
in 96-well plates for 72 h before treatment. They were then
incubated for 72 h with the DAB-Lf dendriplex formulations
at final DNA concentrations ranging from 0.05 to 200 mg/mL,
using naked DNA as a negative control, while DAB: DNA 5:1
ratio served as a positive control. Absorbance was measured
at 570 nm using a plate reader and the growth inhibitory
concentration for 50% of the cells (IC50) was measured. Dose-
response curves were fitted to percentage absorbance values
to obtain IC50 values (three independent experiments, each
performed in quintuplicate).
In vivo study
The in vivo experiments were approved by the local ethics
committee and performed in accordance with the UK Home
Office regulations.
PC-3M-luc-C6 and DU145 cancer cells in exponential
growth were subcutaneously implanted to both flanks of
male immunodeficient BALB/c mice (1 106 cells per flank).
When tumors became palpable, vascularized, and reached a
diameter of 5mm, the animals were split into groups of five
and were treated with DAB-Lf dendriplexes encoding TNFa,
TRAIL, or IL-12, the targeted dendrimer and naked DNA
(50 mg of DNA), via tail vein injection, once every 2 days for
10 days. The weight of the mice was measured daily as a sur-
rogate marker of the toxicity of the treatments and tumor
volume was determined by caliper measurements (vol-
ume¼ d3p/6). Any animal showing a weight loss of 20% or
more of its initial body weight (which demonstrates toxicity
of the treatment) would have to be humanely killed.
The therapeutic efficacy of these treatments was also
assessed by bioluminescence imaging, using an IVIS
Spectrum (Caliper Life Sciences, Hopkinton, MA). To this end,
mice bearing subcutaneous PC-3M-luc-C6 tumors were intra-
venously injected with treatments as described above. Ten
minutes before imaging, they were intraperitoneally injected
with the luciferase substrate D-luciferin (150mg/kg body
weight), and then anesthetized by isoflurane inhalation on
Days 1, 3, 5, 7, 9 of the experiment. The light emitted from
the bioluminescent tumors was detected for 2min using
Living Image
VR
software and displayed as a pseudo-color
overlay onto a gray scale image of the animal. Identical illu-
mination settings were used for acquiring all images.
Statistical analysis
Results were expressed as means ± standard error of the
mean. Statistical significance was assessed by one-way ana-
lysis of variance and Tukey multiple comparison post-test
(Minitab
VR
software, State College, PE). Differences were con-
sidered statistically significant for p values lower than .05.
Results
Synthesis and characterization of Lf-bearing DAB (in
supplementary material) (supplementary figures 2–4)
In vitro biological characterization
In vitro transfection. Lf-bearing DAB dendrimer was found
to increase gene transfection at optimal dendrimer: DNA
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weight ratios compared with DAB on both the tested cell
lines (Figure 1). The highest transfection level was obtained
at dendrimer: DNA weight ratios of 5:1 on PC-3 (Figure 1(a)),
5:1 and 10:1 on DU145 cells (Figure 1(b)). At these ratios,
gene expression following treatment with DAB-Lf dendriplex
(10.54 103±0.43 103U/mL) was 2-fold higher than fol-
lowing treatment with DAB dendriplex (5.17 103±
0.46 103U/mL) in PC3 cells. In DU145 cells, transfection
efficacy of DAB-Lf dendriplex (respectively, 2.23 103±
0.23 103U/mL and 1.99 103±0.18 103U/mL for
dendrimer: DNA weight ratios of 10:1 and 5:1) was lower
than that observed in PC3 cells, but was still significantly
higher than that observed with DAB dendriplex
(1.26 103± 0.17 103). Treatment with naked DNA only
resulted in weak levels of gene expression on both cell lines,
as expected.
Cellular uptake. Qualitative and quantitative analysis. The cel-
lular uptake of fluorescein-labeled DNA carried by DAB-Lf
was qualitatively and quantitatively confirmed in the two
prostate cancer cell lines by confocal microscopy and flow
cytometry (Figure 2). Fluorescein-labeled DNA was
disseminated in the cytoplasm after treatment with both
DAB-Lf and DAB dendriplexes in PC-3 and DU145 cells.
However, the DNA uptake appeared to be more pronounced
in the cells treated with DAB-Lf dendriplex than with DAB
dendriplex. No co-localization of DNA in the nuclei was
visible in any cell lines after 24 h incubation (Figure 2(a)).
These results were quantitatively confirmed by flow
cytometry. Treatment of PC3 cells with DAB-Lf dendriplex
resulted in the highest cellular fluorescence (9004 ± 241
arbitrary units (a.u.)), which was, respectively, 2.1-fold and
19.2-fold higher than that observed after treatment with DAB
dendriplex (4 266± 1 420 a.u.) and DNA solution (469 ± 22
a.u.) (Figure 2(b)). Similarly, the highest cellular fluorescence
in DU145 cells was also observed following treatment with
DAB-Lf dendriplex (5 227 ± 251 a.u.). It was, respectively, 1.6-
fold and 23.8-fold higher than that observed following treat-
ment with DAB dendriplex (3 261± 677 a.u.) and DNA solu-
tion (219 ± 12 a.u.) (Figure 2(c)). Furthermore, treatment of the
cells with naked DNA resulted in a weak uptake for both cell
lines, thus demonstrating the failure of DNA to be taken up by
prostate cancer cells without the assistance of a carrier.
Mechanisms of cellular uptake of DNA complexed to DAB-Lf.
Pre-treatment of PC-3 cells with 80 mM of free Lf significantly
decreased the cellular uptake of fluorescein-labeled DNA
complexed to DAB-Lf, which was 3.9-fold lower than that
observed with DAB-Lf dendriplex without pre-Lf treatment
(respectively, 482 ± 20 a. u. and 1 897± 173 a. u.) (Figures
2(d,e)). The cellular uptake of fluorescein-labeled DNA com-
plexed to DAB-Lf was also partially inhibited by phenylarsine
oxide, filipin, colchicine, and poly-L-lysine in PC-3 cells
(Figures 2(d,e)). Poly-L-lysine caused the most significant
inhibition, with a cellular uptake decreased by 7.9-fold com-
pared to that observed with DAB-Lf dendriplex without
inhibitory treatment (239 ± 8 a.u. following pretreatment with
poly-L-lysine). Phenylarsine oxide and filipin appear to be
partial inhibitors, leading to a cellular uptake decrease by,
respectively, 2.4-fold and 3.1-fold compared to DAB-Lf den-
driplex without pretreatment (respectively, 766 ± 22 a. u. and
597 ± 13 a.u. following pretreatment with phenylarsine oxide
and filipin). Colchicine caused the least inhibition with 1.3-
fold decrease in the cellular uptake (1437 ± 22 a.u following
pretreatment with colchicine).
The uptake of fluorescein-labeled DNA complexed to DAB-
Lf by DU145 cells was also partially inhibited by free Lf, phe-
nylarsine oxide, filipin, colchicine, and poly-L-lysine, following
the same inhibition pattern than that observed in PC-3 cells
(Figures 2(f,g)). Poly-L-lysine caused the most significant
inhibition, with a cellular uptake decreased by 57.8-fold com-
pared to that observed with DAB-Lf dendriplex (respectively,
97 ± 3 a.u. following pretreatment with poly-L-lysine and 5
607 ± 248 a.u. following treatment with DAB-Lf dendriplex).
Colchicine also caused the least inhibition with a non-signifi-
cantly different decrease in the cellular uptake (5374 ± 371
a.u following pretreatment with colchicine). Phenylarsine
oxide and filipin were on this cell line as well partial inhibi-
tors (respectively, 2791 ± 53 a. u. and 381 ± 37 a.u. following
pretreatment with phenylarsine oxide and filipin, correspond-
ing to a cellular uptake decrease by, respectively, 2-fold and
14.7-fold compared to DAB-Lf dendriplex).
Figure 1. Transfection efficacy of DAB-Lf dendriplex at various dendrimer: DNA
weight ratios in PC-3 (a) and DU145 cells (b). Results are expressed as the
mean± SEM of three replicates (n¼ 15). p< .05 versus the highest transfection
ratio.
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Figure 2. Cellular uptake of fluorescein-labeled DNA complexed with DAB-Lf in PC-3 and DU145 cells: (a) Confocal microscopy imaging of the cellular uptake of
fluorescein-labeled DNA (2.5 lg/well) complexed with DAB-Lf, DAB or left uncomplexed, after incubation for 24 h with PC-3 and DU145 cells (Blue: nuclei stained
with DAPI (excitation: 405 nm laser line, bandwidth: 415–491 nm), green: fluorescein-labeled DNA (excitation: 543 nm laser line. bandwidth: 550–620 nm), red: Alexa
Fluor
VR
647 probe (excitation: 633 nm laser line, bandwidth: 650–690 nm) (Bar: 10 mm). (b) Flow cytometry quantification of the cellular uptake of fluorescein-labeled
DNA (5 mg/well) either complexed with DAB-Lf, DAB or left uncomplexed, after incubation for 24 h with PC-3 cells (n¼ 5). p< .05 compared with DAB-Lf-DNA. (c)
As in B, but with DU145 cells. (d) Flow cytometry quantification of the PC-3 cellular uptake of fluorescein- labeled DNA (5mg/well) complexed with DAB-Lf, following
pretreatment with free Lf (80mM) and various cellular uptake inhibitors: phenylarsine oxide (‘PhAsO’), filipin (‘Fil.’), colchicine (‘Colch.’) and poly-L-lysine (‘PLys’)
(n¼ 5), p< .05 compared with DAB-Lf-DNA. (e) Confocal microscopy imaging of the PC-3 cellular uptake of fluorescein-labeled DNA (2.5 lg/well) complexed with
DAB-Lf, following pretreatment with free Lf (80 mM) and various cellular uptake inhibitors: phenylarsine oxide (‘PhAsO’), filipin (‘Fil.’), colchicine (‘Colch.’) and poly-L-
lysine (‘PLys’) (Blue: nuclei stained with DAPI (excitation: 405 nm laser line, bandwidth: 415–491 nm), green: fluorescein-labeled DNA (excitation: 543 nm laser line.
bandwidth: 550–620 nm), red: Alexa Fluor
VR
647 probe (excitation: 633 nm laser line, bandwidth: 650–690 nm) (Bar: 10 mm). (f) As in d, but with DU145 cells (g) As in
e, but with DU145 cells.
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In vitro anti-proliferative activity
The conjugation of Lf to DAB complexed to TNFa, TRAIL, and
IL-12 expression plasmids led to a significant increase of in
vitro antiproliferative activity in PC-3, respectively by 1.9-fold,
3.5-fold, and 5.8-fold for DAB-Lf dendriplexes encoding TNFa,
TRAIL and IL12 when compared to the unconjugated dendri-
plex (Table 1, Supplementary Figure 5). DAB-Lf dendriplex
encoding TNFa was the most efficacious (IC50: 9.97 ± 1.38 mg/
mL), followed by the dendriplex encoding IL-12 (IC50: 10.
84 ± 2.71mg/mL), and then the dendriplex encoding TRAIL
(IC50: 15.62 ± 3.61 mg/mL). The maximum inhibition of prolifer-
ation was reached at a DNA concentration of 80 mg/mL, with
11.9 ± 0.6, 25.3 ± 1.5, and 13.2 ± 0.6% of cells still alive follow-
ing treatment with DAB-Lf dendriplexes encoding TNFa,
TRAIL, and IL12, respectively.
In DU145 cells, the conjugation of Lf to DAB also
improved the anti-proliferative activity of the dendriplex, by
13.2-fold, 5.6-fold, and 1.5-fold for DAB-Lf dendriplexes
encoding TNFa (IC50: 4.34 ± 0.68mg/mL), TRAIL (IC50:
3.03 ± 0.70mg/mL), and IL-12 (IC50: 3.80 ± 0.97mg/mL) (Table 1,
Supplementary Figure 6). The IC50 could not be determined
following treatment of the cells with uncomplexed DAB-Lf,
DAB, and naked DNA. The inhibition of proliferation was
almost complete at a DNA concentration of 32 mg/mL, with 5.
8 ± 1.3, 4.3 ± 0.6, and 3.9 ± 0.1% of cells still alive following
treatment with DAB-Lf dendriplexes encoding TNFa, TRAIL
and IL12, respectively.
In vivo study
Treatment of PC-3 tumors with the three dendriplex formula-
tions (DAB-Lf dendriplexes encoding TNFa, TRAIL, or IL12)
was characterized by a high variability of response to treat-
ment within the same group of mice and an overall reduced
tumor growth compared to naked DNA treatment (Figure
3a). For all of these three treatments, some tumors kept
regressing while others started growing. At Days 14 and 15,
the mice bearing growing tumors had to be euthanized due
to their tumors reaching the maximum allowed size. The
remaining mice, whose tumors were regressing or had com-
pletely disappeared, were kept until the end of the study
(Day 30). By contrast, tumors treated with naked DNA grew
steadily at a growth rate close to that observed for untreated
tumors. Treatment of the DU145 tumors with the three den-
driplex formulations led to a similar pattern of overall slow-
down of tumor growth (Figure 4(a)).
The therapeutic effect resulting from treatment with
DAB-Lf dendriplexes was also qualitatively confirmed by
bioluminescence imaging on mice bearing subcutaneous PC-
3M-luc-C6 tumors (Figure 5). Luciferase expression in the
tumors treated with the three formulations of DAB-Lf dendri-
plexes gradually decreased from Days 1 to 9, whereas all the
other treatments resulted in an increase of luciferase expres-
sion in the growing tumors.
No animal weight loss or apparent signs of toxicity
(marked dyspnea, vocalization, prostration, paleness, hunched
posture, lack of food, or water intake) were observed during
the whole study, thus showing the good tolerability of the
treatments by the mice (Figures 3(b) and 4(b)).
On the last day of the experiment, 70% of PC-3 and 50%
of DU145 tumors treated with DAB-Lf dendriplex encoding
TNFa had completely disappeared, while another 10% of
DU145 tumors showed a partial response (Figures 3(c) and
4(c)). Following treatment with DAB-Lf dendriplex encoding
TRAIL, 40% of PC-3 tumors and 20% of DU145 tumors
showed a complete disappearance, 10% of PC-3 and 30% of
DU145 tumors were regressing. Finally, treatment with DAB-
Lf dendriplex encoding IL-12 resulted in tumor disappearance
of 20% of both PC-3 and DU145 tumors and tumor regres-
sion of 10% on both tumor types. All the tumors treated
with naked DNA or left untreated were progressive for both
tumor types.
The improved therapeutic efficacy observed with DAB-Lf
dendriplexes treatment resulted in an extended survival of,
respectively, 21 and 16 days for PC-3 and DU145 tumors,
compared to untreated tumors (Figures 3(d) and 4(d)).
Discussion
The possibility of using gene therapy for the treatment of
prostate tumors and their metastasis is limited by the inabil-
ity of the current gene delivery systems to specifically reach
their target once intravenously injected, causing secondary
effects to healthy tissues. In order to overcome this issue, we
hypothesize that a Lf-bearing DAB dendrimer complexed to
plasmid DNA encoding TNFa, TRAIL, and IL-12 would
enhance the delivery of therapeutic DNA to prostate tumors
and increase its therapeutic efficacy in vitro as well as in vivo.
The conjugation of Lf to DAB dendrimer was achieved by
a bioconjugation reaction using GMBS as a cross-linker.
GMBS is a heterobifunctional cross-linker with an NHS ester
at one end and a maleimide group at the other end. Thus, a
two-step synthesis technique was used in order to direct the
conjugation reaction towards the selected part of the cou-
pling molecule. The NHS ester was first directed to react with
the primary amine group in DAB to form amide linkages, fol-
lowed by the addition of the targeting ligand. Lf had been
modified prior to the reaction with a sulfhydryl group, to
react with the maleimide, yielding a thioether bond. The
main advantage of this method is that it prevents the poly-
merization that may occur when using homo-bifunctional
cross-linkers. In addition, it offers the highest level of control
over the resultant conjugate size by controlling the molar
ratio of the reactants at each step (Hermanson, 2013).
Table 1. Antiproliferative efficacy of DAB-Lf dendriplexes encoding TNFa,
TRAIL, and IL-12, expressed as IC50 values, in PC-3 and DU145 prostate cancer
cells (n.d.: not determined) (n¼ 15).
IC50 (mg/mL) (mean ± SEM)
Formulation
Cell line DNA DAB-Lf-DNA DAB-DNA DAB-Lf only DAB only DNA only
PC-3 TNFa 9.97 ± 1.38 19.50 ± 3.44 n.d. n.d. n.d.
TRAIL 15.62 ± 3.61 55.74 ± 22.36 n.d. n.d. n.d.
IL-12 10.84 ± 2.71 63.33 ± 37.89 n.d. n.d. n.d.
DU145 TNFa 4.34 ± 0.68 57.38 ± 95.43 n.d. n.d. n.d.
TRAIL 3.03 ± 0.70 17.14 ± 3.78 n.d. n.d. n.d.
IL-12 3.80 ± 0.97 5.92 ± 0.96 n.d. n.d. n.d.
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In contrast to this multi-step method, we previously synthe-
sized DAB-Lf using dimethyl suberimidate as a homo-bifunc-
tional cross-linker (Lim et al., 2015). While this technique
presented the advantage of being fast, it yielded compounds
whose properties were not closely controlled. Variations may
have occurred in the coupling between the reactant com-
pounds, resulting in possible asymmetry in the nanoparticles
formed. The stepwise nature of our modified method over-
comes this disadvantage.
DAB-Lf was able to condense the negatively charged DNA
via electrostatic interactions, although an excess of dendri-
mer (dendrimer: DNA weight ratios of 5:1 and above) was
required to ensure efficient DNA condensation. The DNA con-
densation observed with DAB-Lf appeared to follow the
same pattern as the one described by Kim et al. (2007) and
by Aldawsari et al. (2011) when, respectively, using gener-
ation 2- and 3-polypropylenimine dendrimers conjugated to
positively charged arginine. Both groups demonstrated that
the grafting of arginine residues to the dendrimers facilitated
the formation of stable dendriplexes due to their strong posi-
tive charges at high dendrimer: DNA weight ratios, but
reduced the DNA condensing ability of the dendrimer at low
dendrimer: DNA ratios, as observed in our current experi-
ment. In addition, DNA condensation was improved com-
pared to the results previously obtained with DAB-Lf
synthesized with dimethysuberimidate homo-bifunctional
cross-linker: the DNA condensation has increased by at least
10% depending of the dendrimer: DNA weight ratios (Lim
et al., 2015).
DAB-Lf dendriplex displayed the required size to access
the tumor cells, as the cutoff size for extravasation across
tumor vasculature has been found to be 400 nm for most
tumors (Yuan et al., 1995). Its size decreased with increasing
dendrimer: DNA weight ratios ranging from 0.5:1 until 2:1,
and then reached a plateau. This pattern can be explained
by the fact that higher ratios of charged dendrimers are
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Figure 3. (a) Tumor growth studies in a PC-3 xenograft model after intravenous administration of DAB-Lf dendriplex encoding TNFa (, green), TRAIL (, red), IL-
12 (, blue) (50 mg DNA/injection), DAB-Lf (, brown), naked DNA encoding TNFa (, pale green), naked DNA encoding TRAIL (, orange), naked DNA encoding
IL-12 (, cyan), untreated tumors (, back) (n¼ 5). (b) Variations of the animal body weight throughout the treatment (Color coding as in a) (n¼ 5). (c) Overall
tumor response to treatments at the end of the study, classified in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) (Eisenauer et al.,
2009) (red: progressive response, orange: stable response, yellow: partial response, green: complete response) (n¼ 5). (d) Time to disease progression. The Y axis
gives the proportion of surviving animals over time. Animals were removed from the study once their tumor reached 10mm diameter (Color coding as in a) (n¼ 5).
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more positively charged, therefore more efficient in condens-
ing DNA, which results in the formation of smaller
complexes.
Zeta potential experiments demonstrated that DAB-Lf
dendriplex was bearing a positive surface charge for most
dendrimer: DNA weight ratios, but a negative charge at a
dendrimer: DNA weight ratio of 0.5:1, indicating that nega-
tively charged DNA was not condensed yet with the dendri-
mer at this ratio. This result was consistent with the DNA
condensation and the agarose gel electrophoresis results.
The positive zeta potential for dendrimer: DNA weight ratio
above 0.5:1 is most likely due to the presence of the posi-
tively charged amino acids of Lf. It would eventually lead to
an increase of the electrostatic interactions of the dendri-
plexes with negatively charged cellular membranes, resulting
in an improved cellular uptake through internalization mech-
anisms (Mahato et al., 1999). In addition, DAB-Lf dendriplex
should avoid nonspecific tissue binding in vivo, as its zeta
potential is lower than 30mV (Honary & Zahir, 2013). DAB-Lf
therefore has suitable physicochemical properties for being
efficient gene delivery systems.
In vitro, treatment of the cells with DAB-Lf dendriplex
resulted in an enhanced transfection compared with DAB
on both the tested cell lines. The transfection results
obtained in this study were enhanced compared to those
obtained with DAB-DMSI-Lf on other cancer cell lines. DAB-
DMSI-Lf: DNA dendriplex resulted in a 1.4-fold higher gene
expression compared with unconjugated DAB on A431 and
B16F10 cells (Lim et al., 2015), which is less than the 2.1-
fold increase in cellular uptake observed in PC-3 cells in
the current study. This increased b-gal expression most
likely resulted from the enhanced cellular uptake of this
dendriplex, as there is a strong correlation between cellular
uptake and positive charge density of dendriplexes (Futaki
et al., 2001). These data are in line with the flow cytometer
results of Wei and colleagues (Wei et al., 2012), who found
that the uptake of Lf-bearing liposomes was significantly
enhanced by more than double compared with unmodified
liposomes in hepatocellular carcinoma. DAB-Lf was also
found to increase the uptake of fluorescein-labeled DNA by
2.1-fold compared with unmodified DAB in bEnd.3 brain
cells (Somani et al., 2015).
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Figure 4. As in Figure 3, but in DU145 cells.
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The cellular uptake of fluorescein-labeled DNA complexed
to DAB-Lf was partially inhibited by free Lf, phenylarsine
oxide, filipin, colchicine, and poly-L-lysine.
Pre-treatment of cells with free Lf led to competition
between DAB-Lf dendriplex and free Lf for binding to Lf
receptors, suggesting that the internalization of the DNA
complexed to DAB-Lf is partly due to Lf receptors- mediated
endocytosis. This result is in line with previous publications
examining the effect of free Lf on the uptake of modified
nanomedicines in various cancer cell lines (Lim et al., 2015).
Both phenylarsine oxide and filipin are pinocytosis inhibi-
tors: phenylarsine oxide has been reported to inhibit clathrin-
mediated endocytosis (Visser et al., 2004), while filipin blocks
the caveolae-mediated process in clathrin-independent endo-
cytosis (Kim et al., 2007b). Colchicine is known to inhibit
macropinocytosis (Liu & Shapiro, 2003), which provides non-
specific endocytosis of macromolecules, whereas cationic
poly-L-Lysine acts as an uptake inhibitor for cationic delivery
systems.
The cellular uptake of DNA complexed to DAB-Lf was
therefore mainly related to clathrin-mediated endocytosis,
which is a requisite for Lf receptor-mediated endocytosis,
caveolae-mediated endocytosis, but not macropinocytosis.
This was in accordance with a previous study by Jiang and
colleagues (Jiang et al., 2011), who demonstrated that Lf
could be taken up by colorectal cancer cells via clathrin-
mediated endocytosis. These results therefore confirm the
involvement of Lf receptor-mediated endocytosis and other
nonspecific mechanisms in the cellular internalization of DNA
complexed to DAB-Lf.
Days
1 3 5 7 9
Un
tre
at
ed
D
N
A 
o
n
ly
Cp
lx 
DL
-IL
12
Cp
lx 
DL
-T
RA
IL
Cp
lx 
DL
-T
NF
Figure 5. Bioluminescence imaging of the tumoricidal activity of DAB-Lf dendriplex encoding TNFa (‘cplx DT-TNF’), TRAIL (‘cplx DT-TRAIL’), IL-12 (‘cplx DT-IL12’) in a
PC-3M-luc-C6 tumor model. Controls: naked DNA and untreated tumors. The scale indicates surface radiance (photons/s/cm2/steradian).
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The conjugation of Lf to DAB increased the in vitro anti-
proliferative activity of the dendriplex in the two tested pros-
tate cancer cell lines. The most efficacious treatment
observed in this study was DAB-Lf dendriplex expressing
TRAIL on DU145 cells. These results correlated with the
improved gene expression efficacy following treatment with
DAB-Lf dendriplexes. We could not find any studies describ-
ing the anti-proliferative effect of Lf-bearing gene-based
nanomedicines on prostate cancers to allow a comparison
with our results. However, our results were in accordance
with previously published viral-based works. Kaliberov and
colleagues (2004) have demonstrated that an adenoviral
delivery system encoding TRAIL under the control of the vas-
cular endothelial growth factor receptor FLT1 promoter was
able to increase DU145 cell death compared with the PC-3
cell line, following a similar trend as the one observed in our
study. In our experiments, the IC50 resulting from the treat-
ment of the cells by DAB-Lf dendriplex encoding TNFa was
higher than those of TRAIL and IL-12 in DU145 cells, despite
being the lowest in PC-3 cells. This might be due to the dif-
ferent sensitivity of PC-3 and DU145 prostate cell lines to the
Fas ligand, as Fas-sensitive PC-3 cell line was recently shown
to be more sensitive to TNFa-mediated apoptosis than Fas-
resistant DU145 cell line (Rokhlin et al., 1997). These results,
in line with our observations, suggested that TNFa-mediated
apoptosis in prostate cancer cells might be determined by
factors common in both TNFa and Fas pathways.
In vivo, we demonstrated that novel intravenously admin-
istered DAB-Lf dendriplex encoding TNFa led to tumor eradi-
cation of 70% of PC-3 and 50% of DU145 tumors.
Furthermore, treatment also led to tumor eradication of 40%
of PC-3 tumors and 20% of DU145 tumors completely disap-
peared following treatment with DAB-Lf dendriplex encoding
TRAIL. To our knowledge, it is the first time that the intraven-
ous administration of Lf-bearing gene-based nanomedicines
to mice bearing prostate tumors was able to lead to tumor
regression and even complete tumor suppression in some
cases. We previously demonstrated that DAB-Tf dendriplexes
encoding TNFa, TRAIL, and IL-12 could result in prostate
tumor regression (Al Robaian et al., 2014), but their thera-
peutic efficacy was lower than with DAB-Lf dendriplexes
(respectively, 60% and 10% PC-3 tumor suppression following
treatment with DAB-Tf dendriplexes encoding TNFa and
TRAIL, but 70 and 40% tumor suppression when replacing Tf
by Lf). In addition, DAB-Lf dendriplex encoding TNFa had the
same therapeutic outcome as DAB-Tf dendriplex on DU145
tumors (50% tumor suppression). DAB-Lf dendriplexes encod-
ing TRAIL and IL-12 also led to 20% DU145 tumor suppres-
sion, which was not the case following treatment with DAB-
Tf dendriplexes. Other studies have also demonstrated the
ability of TNFa, TRAIL, and IL-12-encoding DNA to induce a
therapeutic effect on prostate tumors, but using different
modalities of treatment: intra-tumoral injection, use of a virus
as a delivery system or co-treatment with mifepristone
(Gabaglia et al., 2010), radiotherapy (Fujita et al., 2007), onco-
lytic herpes simplex viruses (Varghese et al., 2006), adenoviral
vector-mediated Herpes Simplex Virus/thymidine kinase and
ganciclovir (Nasu et al., 2001). These studies mainly showed a
slowdown of prostate tumor growth, rather than the tumor
regression or suppression observed in some instances in our
experiments.
In vivo experiments were carried out on mice bearing sub-
cutaneous tumors instead of tumors implanted in the pros-
tate, as the antitumoral activity of the treatment had first to
be assessed by monitoring the tumor size by caliper meas-
urement, which requires solid, palpable, and vascularized
subcutaneous tumors. As the intravenous administration of
targeted dendriplexes on nude athymic male mice bearing
subcutaneous tumors resulted in tumor regression, the fol-
low-up experiments will be conducted on mice bearing
orthotopically implanted tumors.
In our study, the most potent therapeutic effects were
obtained following treatment of PC-3 tumors with DAB-Lf
dendriplex encoding TNFa, unlike what was observed in the
in vitro anti-proliferative assay. This discrepancy could be
explained by the fact that TNFa exerts its anti-tumor effects
in vivo via the death receptor-dependent apoptotic pathway,
like TRAIL, but also via its anti-angiogenic effects, that are
critical for its anti-cancer activity (Mocellin et al., 2005;
Mahalingam et al., 2009). In addition, these tumor-targeted
nanomedicines were intravenously injected to the mice,
which would allow them to reach metastases and remote
tumors, an advantage particularly important in the treatment
of prostate tumors.
Conclusions
We have demonstrated for the first time that a Lf-bearing
dendrimer-based gene delivery system complexed to a plas-
mid DNA encoding TNFa, TRAIL, or IL12 can lead to tumor
suppression after intravenous administration.
In vitro, the conjugation of Lf to DAB resulted in a signifi-
cant improvement of the anti-proliferative activity of the den-
driplex by up to 5.8-fold in PC-3 cells compared to the
unmodified dendriplex.
In vivo, the intravenous injection of DAB-Lf dendriplex
encoding TNFa led to a tumor suppression for 70% of PC-3
and 50% of DU145 tumors, while treatment with DAB-Lf den-
driplex encoding TRAIL led to tumor suppression of 40% of
PC-3 tumors and 20% of DU145 tumors. DAB-Lf dendriplex
encoding IL12 also resulted in tumor suppression for 20% of
both types of prostate tumors, with long term survival of the
mice. By contrast, all the tumors treated with the dendrimer,
with naked DNA or left untreated were progressive for both
tumor types. The animals did not show any signs of toxicity.
Lf-bearing DAB dendriplexes encoding TNFa, TRAIL, and
IL-12 therefore hold great potential as a novel approach for
the gene therapy of prostate cancer.
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